
LifeVantage announced a 7.5% boost in revenue year over year, reaching $53.7 million. The Americas region was particularly strong, with an 18.2% increase in revenue, including a 19.5% increase in the United States. Asia Pacific and Europe revenues were down 14.2% with a 16.3% decline in active accounts.

LifeVantage Corporation released its financial report for the second quarter of fiscal 2023, revealing a 2.8% revenue increase over the prior year, reaching $53.7 million.

LifeVantage Corporation announced LV360, a new consultant compensation plan and customer loyalty program that the company describes as “a modern approach to the evolving direct sales industry.”

LifeVantage Corporation reported first quarter fiscal 2023 revenue of $51.8 million, a 2.7% decrease from the same quarter last year.

LifeVantage Corporation announced its financial results for the fourth quarter and full fiscal year that ended June 30, 2022, including fourth quarter revenue of $50.9 million, a 7% decrease from the same period last year. When not accounting for foreign currency fluctuations, this dip was only 3%. The Asia/Pacific and Europe markets actually saw […]

LifeVantage Corporation announced the debut of TrueScience Liquid Collagen, featuring Ruby Red Quinoa Extract and proprietary ingredients that the company says “activate” the body’s collagen production, replenish depleting collagen levels and maintain collagen by reducing breakdown.

In its third fiscal quarter financial report, LifeVantage announced a slight decrease of 3% in revenue from the same period in 2021, totaling $50 million.

LifeVantage Corporation released its financial results for the second quarter of fiscal 2022, announcing an 11.6% decrease in revenue from the prior year and a 1.9% decrease sequentially.

LifeVantage Corporation has officially opened operations in the Philippines through its Philippine subsidiary Protandim Philippines Corporation. With this addition, LifeVantage now has on-the-ground operations in more than 20 countries.

For LifeVantage, a “health and wealth” company whose revenues for the fiscal 2021 year reached $220 million, it’s a focus on improving what’s already working that will define the company’s next season of growth.

Revenue reached $53.2 million, down 2.9% over the same quarter last year and 2.8% sequentially. Adjusted earnings per diluted share were down 8% ($0.23) and adjusted EBITDA was down 13.7% ($5.8 million).